Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.42 |
| ▸ | CHRNG | P07510 | 4/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.42 |
| ▸ | CHRND | Q07001 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | FDPS | P14324 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6187621 | 0.98 | ATM (0.41) | MAOBSLC6A2CHRNB4CHRNA3SLC6A3 | |
| SCHEMBL27647452 | 0.80 | MAOB (0.46) | MAOBSLC6A2CHRNB4CHRNA3SLC6A3 | |
| SCHEMBL6188158 | 0.79 | KDM4E (0.44) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL14850491 | 0.78 | MAOB (0.44) | MAOBSLC6A2CHRNB4CHRNA3SLC6A3 | |
| SCHEMBL10939615 | 0.78 | DPP7 (0.45) | MAOBSLC6A2CHRNB4CHRNA3SLC6A3 | |
| SCHEMBL12462690 | 0.78 | MAOB (0.44) | MAOBSLC6A2CHRNB4CHRNA3SLC6A3 | |
| Hydrochloric Acid SCHEMBL11682964 | 0.78 | MAOB (0.44) | MAOBSLC6A2CHRNB4CHRNA3SLC6A3 | |
| SCHEMBL12937998 | 0.78 | MAOB (0.44) | MAOBSLC6A2CHRNB4CHRNA3SLC6A3 | |
| SCHEMBL94069 | 0.78 | DPP7 (0.45) | MAOBSLC6A2CHRNB4CHRNA3SLC6A3 | |
| SCHEMBL4938808 | 0.78 | DPP7 (0.45) | MAOBSLC6A2CHRNB4CHRNA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493402-B2 | Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2016-11-15 | — | — | US | disclosed |
| EP-1366018-B1 | OMEGA-AMINOALKYLAMIDES OF (R)-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | DOMPÉ FARMACEUTICI S P A (IT) | 2016-07-06 | — | — | EP | disclosed |
| US-20130079514-A1 | \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ | Dompé S.p.A. (IT) | 2013-03-28 | — | — | US | disclosed |
| US-8288368-B2 | inhibitors of the C5a induced chemotaxis; psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, rheumatoid arthritis and in the prevention and the treatment of injury caused by ischemia and reperfusion | DOMPÉ PHA.R.MA S.P.A. (IT) | 2012-10-16 | — | — | US | disclosed |
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | DOMPE PHA.R.MA S.P.A. (IT) | 2008-02-21 | — | — | US | disclosed |
| EP-1084710-B1 | ADENOSINE A1 ANTAGONISTS FOR MALE STERILITY | ASTELLAS PHARMA INC (JP) | 2006-10-18 | — | — | EP | disclosed |
| US-6897214-B2 | Quinazoline derivatives | ZENECA LIMITED (GB) | 2005-05-24 | — | — | US | disclosed |
| US-20050080067-A1 | Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | DOMPE S.P A. (IT) | 2005-04-14 | — | — | US | disclosed |
| EP-0880507-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-08-05 | — | — | US | disclosed |
| US-5296490-A | Pharmaceutically useful pyrazolopyridines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-03-22 | — | — | US | disclosed |
| WO-1993025205-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-12-23 | — | — | WO | disclosed |
| US-5179103-A | Diuretics, hypotensive agents | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1993-01-12 | — | — | US | disclosed |
| EP-0497258-A2 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-5102878-A | Treating psychological, bone, cardiovascular, blood disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5102869-A | Urogenital disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5087629-A | Diuretics, hypotensive agents; cardiotonic agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-11 | — | — | US | disclosed |
| US-4994453-A | Treating asthma, diabetes, obesity, immunosuppression | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| US-4925849-A | DIURETICS, HYPOTENSIVE AGENTS, CARIOTONIC AGENTS AND ANTIEDEMIC AGENTS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| EP-0299209-A2 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | ADORA2A, ADORA1, ADORA2B | MAOB 55/4885SLC6A2 45/4885CHRNB4 72/4885 |
| US-20050080067-A1 | Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | C5AR2, C3AR1, C5AR1 | MAOB 1513/4885SLC6A2 903/4885CHRNB4 2076/4885 |
| US-20130079514-A1 | \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ | C5AR2, C3AR1, C5AR1 | MAOB 1028/4885SLC6A2 780/4885CHRNB4 1310/4885 |
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | C5AR2, C3AR1, C5AR1 | MAOB 1418/4885SLC6A2 1083/4885CHRNB4 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.